ImmunoGenesis Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$44.4M
- Investors
-
11
ImmunoGenesis General Information
Description
Developer of immuno-oncology therapeutics designed to create unparalleled cold tumor treatments. The company specializes in developing immunotherapies to catalyze effective immune responses in immunologically cold cancers such as prostate, colorectal, and pancreatic cancer for the treatment of cancer patients, enabling healthcare professionals to get access to therapies that target key mechanisms of immune resistance.
Contact Information
Website
www.immunogenesis.comCorporate Office
- 2450 Holcombe Boulevard
- Suite J
- Houston, TX 77021
- United States
Corporate Office
- 2450 Holcombe Boulevard
- Suite J
- Houston, TX 77021
- United States
ImmunoGenesis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 02-Apr-2024 | $44.4M | Completed | Clinical Trials - Phase 2 | ||
| 1. Grant | 24-Aug-2020 | Completed | Clinical Trials - Phase 2 |
ImmunoGenesis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 40,751,232 | $0.000100 | $0.58 | $0.58 | 1x | $0.58 | 34.81% | |
| Series A | 55,097,157 | $0.000100 | $0.73 | $0.73 | 1x | $0.73 | 21.05% |
ImmunoGenesis Comparisons
Industry
Financing
Details
ImmunoGenesis Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Perthera | Venture Capital-Backed | McLean, VA |
ImmunoGenesis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ImmunoGenesis Patents
ImmunoGenesis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3490548-A1 | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | Pending | 01-Aug-2016 | ||
| US-20210369746-A1 | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | Pending | 01-Aug-2016 | ||
| JP-2022189827-A | Administration of hypoxia-activated prodrugs in combination with immunomodulators to treat cancer | Pending | 01-Aug-2016 | ||
| EP-3490548-A4 | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | Pending | 01-Aug-2016 | ||
| ES-2872533-T3 | Dna alkylating agents containing aziridine | Active | 24-Jun-2015 | A61K31/396 |
ImmunoGenesis Executive Team (9)
| Name | Title | Board Seat |
|---|---|---|
| James Barlow | Chief Executive Officer, President and Board Member | |
| Federica Pericle Ph.D | Acting Chief Scientific Officer | |
| D.K Strickland | Chief Medical Officer & Consultant | |
| Michael Curran Ph.D | Founder and Scientific Advisory Board Head | |
| Jeremy Barton | Acting Chief Medical Officer |
ImmunoGenesis Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Clifford Stocks | Self | Board Member | |
| James Barlow | ImmunoGenesis | Chief Executive Officer, President and Board Member | |
| Robert Stein Ph.D | Self | Board Member | |
| Ted Koutouzis MD | Reimagined Ventures | Board Member | |
| Thomas Barton | Self | Board Member |
ImmunoGenesis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ImmunoGenesis Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ADIT Ventures | Venture Capital | Minority | ||
| BioAdvance | Venture Capital | Minority | ||
| Cancer Focus Fund | Venture Capital | Minority | ||
| Denniston Family Office | Family Office | Minority | ||
| Juno Capital (United States) | Venture Capital | Minority |
ImmunoGenesis FAQs
-
When was ImmunoGenesis founded?
ImmunoGenesis was founded in 2019.
-
Who is the founder of ImmunoGenesis?
Michael Curran Ph.D and William Tanner Ph.D are the founders of ImmunoGenesis.
-
Who is the CEO of ImmunoGenesis?
James Barlow is the CEO of ImmunoGenesis.
-
Where is ImmunoGenesis headquartered?
ImmunoGenesis is headquartered in Houston, TX.
-
What is the size of ImmunoGenesis?
ImmunoGenesis has 14 total employees.
-
What industry is ImmunoGenesis in?
ImmunoGenesis’s primary industry is Drug Discovery.
-
Is ImmunoGenesis a private or public company?
ImmunoGenesis is a Private company.
-
What is the current valuation of ImmunoGenesis?
The current valuation of ImmunoGenesis is .
-
What is ImmunoGenesis’s current revenue?
The current revenue for ImmunoGenesis is .
-
How much funding has ImmunoGenesis raised over time?
ImmunoGenesis has raised $44.4M.
-
Who are ImmunoGenesis’s investors?
ADIT Ventures, BioAdvance, Cancer Focus Fund, Denniston Family Office, and Juno Capital (United States) are 5 of 11 investors who have invested in ImmunoGenesis.
-
Who are ImmunoGenesis’s competitors?
NexImmune, Aura Biosciences, Arcus Biosciences, Sutro Biopharma, and Perthera are some of the 6 competitors of ImmunoGenesis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
